Cory Renauer
Value, research analyst, biotech, small-cap

Why Aegerion Is Worth 1,732 Times Sales

In the first quarter of 2013, Aegerion Pharmaceuticals (NASDAQ:AEGR) posted its first revenues ever. At its recent price of about $74, the company's shares are trading at about 1,732 times trailing twelve month sales. If you think that's a bit steep for a biotech with a single product, you're not alone.

(click to enlarge)

I'm going to show you why this company's lone product, recently approved in the US for the treatment of one ultra-rare disease, makes Aegerion's recent price seem not just reasonable, but undervalued.

Good news from the EU

On June 3, Aegerion Pharmaceuticals made a special call to announce a very positive response [pdf] from the European Medicines Agency's [EMA] Committee for Medicinal...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details